NCX 4040 is primarily investigated for its potential therapeutic applications, particularly in the field of oncology. It is a nitric oxide-releasing derivative of aspirin, designed to combine the anti-inflammatory and antiplatelet effects of aspirin with the tumor-suppressive properties of nitric oxide. This dual mechanism makes it a promising candidate for cancer treatment, especially in colorectal cancer, where it has shown efficacy in preclinical studies by inducing apoptosis and inhibiting tumor growth. Additionally, its ability to release nitric oxide may help overcome resistance to conventional therapies, making it a potential adjunct in cancer treatment regimens. Research is ongoing to explore its broader applications in other types of cancers and inflammatory diseases.